XLRN News and Press, Acceleron Pharma Inc. From 10/06/20

Acceleron will start a Phase 3 sotatercept for PAH trial by year end. Q3 results should show continuing good Reblozyl revenue ramp. It is possible sotatercept will see commercial sales in 2023 or earlier. For further details see: Acceleron Pharma Plan For Sotatercept Add...

Four not-widely-followed biotech stocks were pitched at the recent Ira Sohn conference. Below is the full audio of the pitches, and a list of the publicly-traded landscape for each. For further details see: These Are The Four Biotech Stocks Recently Pitched At The Ira Sohn Conference

REBLOZYL ® is the first and only erythroid maturation agent approved for use in Canada Bristol Myers Squibb Canada (BMS) and Acceleron Pharma Inc. (NASDAQ:XLRN) announced today that Health Canada has approved REBLOZYL ® (luspatercept) for the treatment of a...

Acceleron Pharma Inc. (Nasdaq: XLRN), a leading biopharmaceutical company in the discovery, development, and commercialization of TGF-beta superfamily therapeutics to treat serious and rare diseases, today announced it will host a conference call and webcast for investors and analysts on Frid...

Acceleron Pharma Inc. (Nasdaq:XLRN), a leading biopharmaceutical company in the discovery, development, and commercialization of TGF-beta superfamily therapeutics to treat serious and rare diseases, announced today the appointment of Laura J. Hamill to its Board of Directors. Ms. Hamill br...

Acceleron ( XLRN ) reported a strong second quarter of 2020 on August 6. Revenue was $39.8 million, up sequentially from $4.3 million and up from the year-earlier figure of $27.7 million. Of that, Reblozyl royalty revenue in Q2 was $11.1 million, up sequentially from $1.5 million. Reblozyl (...

Acceleron Pharma Inc. (XLRN) Q2 2020 Earnings Conference Call August 6, 2020 5:00 PM ET Company Participants Jamie Bernard – Associate Director-Investor Relations Habib Dable – Chief Executive Officer Kevin McLaughlin – Chief Financial Officer Sujay Kango &...

Image source: The Motley Fool. Acceleron Pharma Inc   (NASDAQ: XLRN) Q2 2020 Earnings Call Aug 6, 2020 , 5:00 p.m. ET Operator Continue reading

The following slide deck was published by Acceleron Pharma Inc. in conjunction with their 2020 Q2 earnings Read more ...

Acceleron Pharma (NASDAQ: XLRN ) : Q2 GAAP EPS of -$0.34 beats by $0.20 . More news on: Acceleron Pharma Inc., Earnings news and commentary, Healthcare stocks news, Read more ...